3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Hepatocellular
19
Neoplasm Metastasis
13
Melanoma
12
Nasopharyngeal Carcinoma
10
Carcinoma, Non-Small-Cell Lung
10
Stomach Neoplasms
8
Rectal Neoplasms
8
Pancreatic Neoplasms
8
Colorectal Neoplasms
8
Squamous Cell Carcinoma of Head and Neck
6
Neoplasms
6
Locally Advanced Rectal Cancer
6
Carcinoma, Renal Cell
6
Uterine Cervical Neoplasms
4
Recurrence
4
Lymphoma, Extranodal NK-T-Cell
4
Triple Negative Breast Neoplasms
3
Sarcoma
3
Nasopharyngeal Neoplasms
3
Glioblastoma
3
Esophageal Squamous Cell Carcinoma
3
Esophageal Neoplasms
3
Cholangiocarcinoma
3
Thyroid Neoplasms
2
Solid Tumor
2
Prostatic Neoplasms
2
Lymphoma
2
Lung Neoplasms
2
Kidney Neoplasms
2
Gastrointestinal Stromal Tumors
2
Interventions
Diathermy
20
Radiotherapy
11
Fluorouracil
4
Drug Therapy
4
Cisplatin
4
Radiation
3
Immune Checkpoint Inhibitors
3
Brachytherapy
3
tislelizumab
2
Surgical Procedures, Operative
2
Solutions
2
Immunotherapy
2
Hyperthermia, Induced
2
Hydrogen Peroxide
2
Conization
2
Capecitabine
2
spartalizumab
1
anlotinib
1
Temozolomide
1
Saline Solution
1
Radiation Dose Hypofractionation
1
Patient Reported Outcome Measures
1
Paclitaxel
1
Oxaliplatin
1
Mitomycin
1
Ifosfamide
1
Hyperthermic Intraperitoneal Chemotherapy
1
Gemcitabine
1
Folfox protocol
1
Doxorubicin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Hyperthermia
×
spartalizumab
×
Clear all
NCT06022692
2023-09-05
HEAIS001
Zhejiang Hospital
Phase 1/2
Completed
18 enrolled